Latest news with #EditCoBio
Business Wire
22-04-2025
- Business
- Business Wire
EditCo Bio and Promega Partner to Power a New Era of Biologically Relevant Cell-Based Research
REDWOOD CITY, Calif.--(BUSINESS WIRE)--EditCo Bio, Inc. has announced a strategic licensing agreement with Promega Corporation, granting EditCo access to Promega HiBiT, HaloTag®, and NanoLuc® technologies. These advanced protein-tagging and bioluminescent detection systems will be integrated into EditCo's CRISPR knock-in services. This collaboration strengthens EditCo's position as a leader in engineered cell solutions by enabling researchers to generate highly reproducible and reliable gene-edited models for a wide range of applications. Through this agreement, EditCo will not only facilitate precise genomic knock-ins but also offer functional validation services, ensuring that engineered cells maintain proper protein expression, stability, and activity. These capabilities empower researchers with cell models optimized for mechanistic studies, drug screening, and other advanced applications requiring quantitative protein analysis. 'Our collaboration with Promega underscores EditCo's commitment to delivering industry-leading CRISPR-engineered cells that go beyond genetic modification by incorporating functional validation,' said Travis Maures, PhD, Chief Scientific Officer at EditCo Bio. 'By integrating HiBiT, HaloTag, and NanoLuc into our knock-in workflows, we provide researchers with powerful tools to track protein expression, interactions, and activity with high sensitivity and accuracy. This partnership will accelerate discoveries in functional genomics, drug development, and therapeutic research.' 'This agreement accelerates scientific innovation by providing researchers with advanced cellular models engineered for precise functional analysis,' says Tom Livelli, Promega Vice President, Life Sciences. 'Leveraging these technologies enables scientists to probe protein dynamics directly within living cells, empowering deeper insights into complex biological mechanisms.' Expanding Functional Assays with HiBiT, HaloTag, and NanoLuc NanoLuc: A highly sensitive luciferase enzyme that provides an exceptional bioluminescent signal for real-time monitoring of cellular and molecular processes. HiBiT: A small bioluminescent peptide tag that enables sensitive, quantitative analysis of protein expression and interactions in live cells. HaloTag: A versatile protein labeling system that allows covalent attachment of fluorescent and bioluminescent probes for imaging, protein interaction studies, and biochemical assays. EditCo's licensing agreement with Promega enables the development of custom-engineered cell lines incorporating these technologies exclusively for research use. Researchers can leverage these advanced tools to create reliable and reproducible cellular models with functional validation, streamlining experimental workflows and increasing data confidence. For more details on EditCo's CRISPR Knock-in Services featuring HiBiT, HaloTag, and NanoLuc, visit About EditCo Bio, Inc. EditCo Bio is a leader in engineered cell solutions, offering high-quality, functionally validated CRISPR-edited cell lines. With a strong foundation in CRISPR genome engineering, EditCo Bio provides researchers with precise, reproducible, and scalable gene-editing services to advance discoveries in cell and gene therapy, drug development, and basic research. About Promega Corporation Promega Corporation develops innovative technologies for nucleic acid and protein analysis, including proprietary tools like HaloTag®, NanoLuc®, and HiBiT. For over 45 years, its products have advanced research in drug discovery, molecular biology, and diagnostics. Headquartered in Madison, WI, Promega operates in 16 countries with over 50 global distributors. Learn more at
Associated Press
28-01-2025
- Science
- Associated Press
EditCo Bio, Inc. Launches XDel Knockout Cells: Redefining CRISPR Gene Editing Efficiency and Reproducibility
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 28, 2025-- EditCo Bio, a leader in cutting-edge genetic engineering and cellular model solutions, today announced the launch of XDel Knockout Cells, an innovative product designed to revolutionize the field of CRISPR gene editing. By leveraging a groundbreaking guide RNA (gRNA) design strategy, XDel technology ensures robust, reliable, and reproducible gene knockout results that accelerate research in functional genomics, disease modeling, and drug development. Unmatched Quality and Efficiency XDel Knockout Cells outperform traditional single-guide RNA (sgRNA) CRISPR methods, delivering significantly higher on-target editing efficiency while minimizing off-target effects. With a unique multiple guide RNA design, XDel technology utilizes up to three intelligently coordinated gRNAs to create efficient and consistent fragment deletions in target genes. This approach ensures persistent protein depletion and eliminates the variability often encountered with single-guide methods. Key Benefits of XDel Knockout Technology: Different Formats and Cell Types to Meet Research Needs XDel Knockout Cells are available in a variety of customizable formats, including cell pools, cell clones, and engineered cell libraries. Researchers can select from immortalized cells or induced pluripotent stem cells (iPSCs), either customer-supplied or EditCo-supplied, ensuring compatibility with diverse experimental workflows. Driving Discovery Forward 'XDel Knockout Cells are designed to empower researchers with the confidence and reproducibility they need in guaranteed CRISPR knockouts to drive groundbreaking discoveries with ease,' said Travis Maures, CSO of EditCo Bio. 'With novel XDel technology and the freedom to easily order reliable knockout cell pools and clones across cell types, we are setting a new benchmark for CRISPR gene editing, democratizing CRISPR and making complex experiments simpler and more efficient.' The introduction of XDel Knockout Cells is a strategic extension of EditCo's comprehensive Engineered Cell portfolio. It further solidifies the company's position as a leader in cell engineering solutions that includes precision knockout and knock-in technologies across cell types, including immortalized, iPS, and primary cell lines like T cells and fibroblasts. To learn more about XDel Knockout Cells, visit or contact EditCo at About EditCo Bio, Inc. EditCo Bio is a pioneer in the development of CRISPR-engineered cell models and high-throughput gene editing solutions. Originally a spinout of Synthego, EditCo Bio leverages the expertise, technology, and partnerships that are critical for creating a novel, end-to-end CRISPR platform able to accelerate scientific discoveries. They're dedicated to building out a more accessible research toolkit to make genome engineering easier, faster, and more reliable. To learn more about EditCo Bio, visit our website at Lindsey Wolf SOURCE: EditCo Bio, Inc. Copyright Business Wire 2025. PUB: 01/28/2025 01:00 PM/DISC: 01/28/2025 01:00 PM
